Pfizer UK increases its production of ventilation drugs for NHS patients by threefold over 6 months

Ben Osborn, Managing Director of Pfizer UK, has highlighted that the drug manufacturer has increased its production of ventilation drugs for UK NHS patients by threefold over the past six months.

A spokesperson for Pfizer UK confirmed that Osborn was referring to an increase in production of multiple drugs and that the drug manufacture has an established history of delivering during crises’.

Osborn stated: “We know exactly the medicines that will be required if we see the peak continue to increase in wave 2. We’ve already started to scale up manufacturing in regard to that around the world and we know what we would need here in the UK.”